Luhua Lai

Prof. Dr. Luhua Lai

College of Chemistry and Molecular Engineering, Peking University, Beijing, China
orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2017 in Science
Verified
Journal Article
Closed access
PDF file
ZGZengxiang Ge
Zengxiang Ge
Tabata BergonciTabata Bergonci
Tabata Bergonci
YZYuling Zhao
Yuling Zhao
YZYanjiao Zou
Yanjiao Zou
SDShuo Du
Shuo Du
LQLi-Jia Qu
Li-Jia Qu
Timing a switch in tissue integrity: In plants, sperm cells travel through the pollen tube as it grows toward the ovule. Successful fertilization depends on the pollen tube rupturing to release the sperm cells (see the Perspective by Stegmann and Zipfel). Ge et al. and Mecchia et al. elucidated the intercellular cross-talk that maintains pollen tube integrity during growth but destroys it at just the right moment. The signaling peptides RALF4 and RALF19, derived from the pollen tube, maintain its integrity as it grows. Once in reach of the ovule, a related signaling peptide, RALF34, which derives from female tissues, takes over and causes rupture of the pollen tube. Science , this issue p. 1596 , p. 1600 ; see also p. 1544

13 October 2015 in Journal of Chemical Information and Modeling
Verified
Journal Article
Open access
YXYoujun Xu
Youjun Xu
ZDZiwei Dai
Ziwei Dai
FCFangjin Chen
Fangjin Chen
SGShuaishi Gao
Shuaishi Gao
JPJianfeng Pei
Jianfeng Pei
LLLuhua Lai
Luhua Lai
Drug-induced liver injury (DILI) has been the single most frequent cause of safety-related drug marketing withdrawals for the past 50 years. Recently, deep learning (DL) has been successfully applied in many fields due to its exceptional and automatic learning ability. In this study, DILI prediction models were developed using DL architectures, and the best model trained on 475 drugs predicted an external validation set of 198 drugs with an accuracy of 86.9%, sensitivity of 82.5%, specificity of 92.9%, and area under the curve of 0.955, which is better than the performance of previously described DILI prediction models. Furthermore, with deep analysis, we also identified important molecular features that are related to DILI. Such DL models could improve the prediction of DILI risk in humans. The DL DILI prediction models are freely available at http://www.repharma.cn/DILIserver/DILI_home.php.

16 July 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
CCChenjing Cai
Chenjing Cai
SWShiwang Wang
Shiwang Wang
YXYoujun Xu
Youjun Xu
WZWeilin Zhang
Weilin Zhang
KTKe Tang
Ke Tang
JPJianfeng Pei
Jianfeng Pei

10 May 2018 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
YXYoujun Xu
Youjun Xu
SWShiwei Wang
Shiwei Wang
QHQiwan Hu
Qiwan Hu
SGShuaishi Gao
Shuaishi Gao
XMXiaomin Ma
Xiaomin Ma
JPJianfeng Pei
Jianfeng Pei
CavityPlus is a web server that offers protein cavity detection and various functional analyses. Using protein three-dimensional structural information as the input, CavityPlus applies CAVITY to detect potential binding sites on the surface of a given protein structure and rank them based on ligandability and druggability scores. These potential binding sites can be further analysed using three submodules, CavPharmer, CorrSite, and CovCys. CavPharmer uses a receptor-based pharmacophore modelling program, Pocket, to automatically extract pharmacophore features within cavities. CorrSite identifies potential allosteric ligand-binding sites based on motion correlation analyses between cavities. CovCys automatically detects druggable cysteine residues, which is especially useful to identify novel binding sites for designing covalent allosteric ligands. Overall, CavityPlus provides an integrated platform for analysing comprehensive properties of protein binding cavities. Such analyses are useful for many aspects of drug design and discovery, including target selection and identification, virtual screening, de novo drug design, and allosteric and covalent-binding drug design. The CavityPlus web server is freely available at http://repharma.pku.edu.cn/cavityplus or http://www.pkumdl.cn/cavityplus.

1 January 2004 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
KFKeqiang Fan
Keqiang Fan
PWPing Wei
Ping Wei
QFQian Feng
Qian Feng
SCSidi Chen
Sidi Chen
CHChangkang Huang
Changkang Huang
LLLuhua Lai
Luhua Lai
The 3C-like proteinase of severe acute respiratory syndrome (SARS) coronavirus has been proposed to be a key target for structural-based drug design against SARS. In order to understand the active form and the substrate specificity of the enzyme, we have cloned, expressed, and purified SARS 3C-like proteinase. Analytic gel filtration shows a mixture of monomer and dimer at a protein concentration of 4 mg/ml and mostly monomer at 0.2 mg/ml, which correspond to the concentration used in the enzyme assays. The linear decrease of the enzymatic-specific activity with the decrease of enzyme concentration revealed that only the dimeric form is active and the dimeric interface could be targeted for structural-based drug design against SARS 3C-like proteinase. By using a high pressure liquid chromatography assay, SARS 3C-like proteinase was shown to cut the 11 peptides covering all of the 11 cleavage sites on the viral polyprotein with different efficiency. The two peptides corresponding to the two self-cleavage sites are the two with highest cleavage efficiency, whereas peptides with non-canonical residues at P2 or P1′ positions react slower. The P2 position of the substrates seems to favor large hydrophobic residues. Secondary structure studies for the peptide substrates revealed that substrates with more β-sheetlike structure tend to react fast. This study provides a basic understanding of the enzyme catalysis and a full substrate specificity spectrum for SARS 3C-like proteinase, which are helpful for structural-based inhibitor design against SARS and other coronavirus.

1 January 2021 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Open access
HLHongbo Liu
Hongbo Liu
FYFei Ye
Fei Ye
QSQi Sun
Qi Sun
HLHao Liang
Hao Liang
CLChunmei Li
Chunmei Li
LLLuhua Lai
Luhua Lai
COVID-19 has become a global pandemic and there is an urgent call for developing drugs against the virus (SARS-CoV-2). The 3C-like protease (3CLpro) of SARS-CoV-2 is a preferred target for broad spectrum anti-coronavirus drug discovery. We studied the anti-SARS-CoV-2 activity of S. baicalensis and its ingredients. We found that the ethanol extract of S. baicalensis and its major component, baicalein, inhibit SARS-CoV-2 3CLpro activity in vitro with IC50’s of 8.52 µg/ml and 0.39 µM, respectively. Both of them inhibit the replication of SARS-CoV-2 in Vero cells with EC50’s of 0.74 µg/ml and 2.9 µM, respectively. While baicalein is mainly active at the viral post-entry stage, the ethanol extract also inhibits viral entry. We further identified four baicalein analogues from other herbs that inhibit SARS-CoV-2 3CLpro activity at µM concentration. All the active compounds and the S. baicalensis extract also inhibit the SARS-CoV 3CLpro, demonstrating their potential as broad-spectrum anti-coronavirus drugs.